PPV23
1 paper
- Human trial1
Latest
Frontiers in Immunology
Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study
Randomized trial in 636 peopleInterventions